Trondheim Norway-based early-stage therapeutic company APIM Therapeutics has raised additional funding.
Led by CEO Konstantinos Alevizopoulos and based on research by Prof. M. Otterlei and co-workers (National Institute of Science and Technology, Trondheim, Norway), APIM Therapeutics is pursuing novel synthetic lethal drug approaches to selective cancer cell elimination using proprietary peptides in combination with a wide range of chemotherapeutic drugs currently used in the clinic. The company focuses on peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), an emerging cancer drug target implicated in the regulation of cellular responses to DNA damage and stress.
APIM intends to use the funds to further advance preclinical development of its anti-cancer lead compound, ATX-101, which has already shown promising anti-cancer activity in several blood and solid tumor cancer models in preclinical assays in vitro and in vivo and is currently being developed as a novel selective anti-cancer treatment targeting DNA repair and cell cycle control in tumor cells.
21/03/2011: APIM Therapeutics Closes Additional Seed Funding Round
27/05/2011: APIM Therapeutics AS Raises €440,000